Drugs that contain Pasireotide Pamoate

1. List of Signifor Lar Kit drug patents

Can you believe SIGNIFOR LAR KIT received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7473761 RECORDATI RARE Somatostatin analogues
Dec, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822637 RECORDATI RARE Somatostatin analogues
Aug, 2023

(4 months from now)

US7759308 RECORDATI RARE Microparticles comprising somatostatin analogues
Oct, 2026

(3 years from now)

US9351923 RECORDATI RARE Extended-release composition comprising a somatostatin derivative in microparticles
May, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 29, 2025

Market Authorisation Date: 15 December, 2014

Treatment: Method of treating acromegaly

Dosage: FOR SUSPENSION;INTRAMUSCULAR

More Information on Dosage

SIGNIFOR LAR KIT family patents

11

United States

8

European Union

5

Korea, Republic of

4

Australia

4

Norway

3

Israel

3

South Africa

3

Denmark

3

Mexico

3

Slovenia

3

Argentina

3

Brazil

3

Portugal

3

Malaysia

3

Spain

3

Peru

3

Poland

3

Taiwan, Province of China

3

China

3

Ecuador

3

United Kingdom

3

Japan

3

Canada

3

New Zealand

2

Austria

2

Hong Kong

2

Russia

2

Morocco

2

Hungary

2

Germany

2

Cyprus

2

Luxembourg

2

Tunisia

1

El Salvador

1

Slovakia

1

Belgium

1

Uruguay

1

Cuba

1

Costa Rica

1

Colombia

1

Honduras

1

Croatia

1

Guatemala

1

Dominican Republic

1

Czech Republic

1

San Marino

1

Iceland

1

Chile

1

Nicaragua

1

Ukraine

1

Georgia

EA

1

EA

1

Panama

1

ME

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic